In response to the rising burden of high blood pressure in India, Cadila Pharmaceuticals has introduced a new triple combination therapy, ‘Silej Trio’, designed to simplify and strengthen hypertension management. The single-pill solution combines three widely used medications, offering a more convenient and potentially more effective approach for patients dealing with long-term blood pressure issues.
Hypertension continues to be a major public health concern in India, affecting an estimated 220 million people. Despite its prevalence, many cases remain undiagnosed or poorly managed due to irregular treatment and complex medication routines. This often increases the risk of serious complications such as heart disease and stroke. In this backdrop, ‘Silej Trio’ aims to address both effectiveness and adherence by reducing the number of pills a patient needs to take daily.
The newly launched therapy is a fixed-dose combination of three established drugs: Cilnidipine, Telmisartan, and Metoprolol. Each of these components plays a distinct role in controlling blood pressure. Cilnidipine works by relaxing blood vessels, allowing smoother blood flow. Telmisartan helps regulate hormonal activity that influences blood pressure, while Metoprolol stabilises heart rate and reduces cardiac workload. Together, they provide a comprehensive approach to managing hypertension through multiple pathways.
One of the key advantages of this triple combination is its potential to improve patient compliance. Many individuals with hypertension are required to take multiple medications at different times of the day, which can lead to missed doses. By combining three therapies into a single pill, ‘Silej Trio’ simplifies the treatment regimen, making it easier for patients to stay consistent with their medication.
Another important aspect of the drug is its reported safety and tolerability profile. Compared to conventional treatment options, the combination is said to reduce common side effects, including peripheral oedema or leg swelling, which is often associated with certain blood pressure medications. This could make it a more comfortable long-term option for patients.
The therapy is built on advanced Tri-Tab technology, which features a three-layered tablet design. This structure ensures that each component of the drug is released in a controlled manner, improving absorption and maintaining steady blood pressure levels throughout the day. The sustained release mechanism also contributes to enhanced cardiac protection, an essential factor in patients with co-existing cardiovascular conditions.
Medical experts suggest that fixed-dose combination therapies like ‘Silej Trio’ could play a crucial role in the future of hypertension care. By targeting multiple mechanisms within the body and simplifying treatment routines, such innovations have the potential to improve outcomes and reduce the overall burden of cardiovascular diseases.
With the launch of ‘Silej Trio’, Cadila Pharmaceuticals is aiming to offer a more practical and patient-friendly solution in the fight against hypertension, marking a significant step forward in India’s evolving healthcare landscape.
Subscribe Deshwale on YouTube
